Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects
2011/07/12 by Ethan B Russo, Ethan B. Russo · 35 citations
Medicine · Agricultural and Biological Sciences · Nursing · #Cannabis and Cannabinoid Research #GABA and Rice Research #Biochemical Analysis and Sensing Techniques
paper · pdf · doi:10.1111/j.1476-5381.2011.01238.x
Abstract
Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene, exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study. This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol and phytol. Terpenoids share a precursor with phytocannabinoids, and are all flavour and fragrance components common to human diets that have been designated Generally Recognized as Safe by the US Food and Drug Administration and other regulatory agencies. Terpenoids are quite potent, and affect animal and even human behaviour when inhaled from ambient air at serum levels in the single digits ng·mL(-1) . They display unique therapeutic effects that may contribute meaningfully to the entourage effects of cannabis-based medicinal extracts. Particular focus will be placed on phytocannabinoid-terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin-resistant Staphylococcus aureus). Scientific evidence is presented for non-cannabinoid plant components as putative antidotes to intoxicating effects of THC that could increase its therapeutic index. Methods for investigating entourage effects in future experiments will be proposed. Phytocannabinoid-terpenoid synergy, if proven, increases the likelihood that an extensive pipeline of new therapeutic products is possible from this venerable plant. http://dx.doi.org/10.1111/bph.2011.163.issue-7.
Citations
Cited by
- Optimal pain management for patients with cancer in the modern era
- Analgesic Potential of Terpenes Derived from Cannabis sativa
- Examining the profile of high-potency cannabis and its association with severity of cannabis dependence
- α-Pinene: A never-ending story
- Hemp Extract (Extractum Cannabis) in the Treatment of Gastrointestinal Distress and Dyspepsia: Historical Insights from Barcelona, Spain
- Synthetic Biology of Cannabinoids and Cannabinoid Glucosides in Nicotiana benthamiana and Saccharomyces cerevisiae
- Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis
- Safety and Tolerability of Low-Dose Full-Spectrum Cannabidiol in Long-Term Virally Suppressed Adults with HIV: A Randomized Double-Blind Placebo-Controlled Trial
- Evolution and Classification of Cannabis sativa (Marijuana, Hemp) in Relation to Human Utilization
- Does the “Entourage Effect” in Cannabinoids Exist? A Narrative Scoping Review
- The draft genome and transcriptome of Cannabis sativa. [europepmc]
- Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. [europepmc]
- Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. [europepmc]
- Cannabinoids and Epilepsy. [europepmc]
- Cannabis sativa: The Plant of the Thousand and One Molecules. [europepmc]
- The Role of the Endocannabinoid System in the Brain-Gut Axis. [europepmc]
- Terpene synthases from Cannabis sativa. [europepmc]
- The endocannabinoid system as a target for novel anxiolytic drugs. [europepmc]
- Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? [europepmc]
- Optimal pain management for patients with cancer in the modern era. [europepmc]
- A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis. [europepmc]
- Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. [europepmc]
- Cannabinoid Delivery Systems for Pain and Inflammation Treatment. [europepmc]
- Cannabinoids and Pain: New Insights From Old Molecules. [europepmc]
- An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. [europepmc]
- Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities. [europepmc]
- The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No "Strain," No Gain. [europepmc]
- Changing landscape of cannabis: novel products, formulations, and methods of administration. [europepmc]
- The "Entourage Effect": Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders. [europepmc]
- Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. [europepmc]
- Secondary Metabolites Profiled in Cannabis Inflorescences, Leaves, Stem Barks, and Roots for Medicinal Purposes. [europepmc]
- Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis. [europepmc]
- The Cannabis Terpenes. [europepmc]
- Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis . [europepmc]
- Major Phytochemicals: Recent Advances in Health Benefits and Extraction Method. [europepmc]
Related